Save the Date!

Cholangiocarcinoma Foundation Annual Conference
February 4-5, 2016
Salt Lake City, Utah

In cooperation with:

2015 Annual Conference in Review

Welcome to the Conference/Foundation Updates

Dr. Robin Kim, Huntsman Cancer Institute

Dr. Milind Javle, MD Anderson Cancer Center – Conference Chair

Stacie Lindsey, President, The Cholangiocarcinoma Foundation

Somatic Mutation Profiling in Cholangiocarcinoma

Dr. Laura Wood, Johns Hopkins University School of Medicine


Oral Abstract Presentation - Massive Parallel Sequencing Uncovers Actionable FGFR2-PPHLN1 Fusion and ARAF Mutations in Intrahepatic Cholangiocarcinoma

Dr. Daniela Sia, Icahn School of Medicine at Mount Sinai


Tumor Profiling and Investigational Therapeutics

Dr. Funda Meric-Bernstam, MD Anderson Cancer Center


BAP1 Mutations-Spectrum and Biology in Cancer

Dr. Michele Carbone, University of Hawaii

No presentation is available at this time.

Clinical Trials in Cholangiocarcinoma: ABC Experience

Dr. John Bridgewater, UCL Cancer Institute

No slides available at this time

Oral Abstract Presentation - Gemcitabine, Capecitabine & Bevacizumab in Patients with Advanced BC- Final Results of a Multicenter Phase II Study

Dr. Renuka Iyer, Roswell Park Cancer Institute


CCF Nursing Advisory Board Update

Sue Acquisto, CCF Nursing Advisory Board Chair

NAB Presentation 2015

CCF Working Group Updates

Dr. Milind Javle, MD Anderson – Conference Chair

Dr. Lipika Goyal,Massachusetts General Hospital Cancer Center

Dr. Renuka Iyer, Roswell Park Cancer Institute

Dr. R. Kate (Katie) Kelley, University of California San Francisco

Dr. Kelley’s Presentation Dr. Goyal’s Presentation Dr. Iyer’s Presentation




Targeting FGFR Alterations in Cancer with a Selective FGFR Inhibitor

Dr. Randi Isaacs, Novartis Institute for BioMedical Research


IDH1 Mutation in Cholangiocarcinoma

Kate Yen, Agios Pharmaceutical


Oral Abstract Presentation - Using Model Systems to Understand IDH Mutant Cholangiocarcinoma

Dr. Supriya Saha, Massachusetts General Hospital Cancer Center


Liver Development and Plasticity

Dr. Ben Stanger, University of Pennsylvania


Potential of Immunotherapy for Solid Tumors including Cancers of the Bile Duct

Dr. Lei Zheng, Johns Hopkins University School of Medicine


CCF Advocacy Overview

Marion Schwartz, CCF Chief Advocacy Officer


PSC and Surveillance for Cholangiocarcinoma

Dr. Keith Lindor, Arizona State University


Oral Abstract Presentation - Conjugated Bile Acids Promote Cholangiocarcinoma Cell Invasive Growth via Activation of Sphingosine 1-phosphate Receptor 2

Dr. Huiping Zhou, Virginia Commonwealth University



Oral Abstract Presentation - Retrospective Review of Treatment Given to Unresectable Cholangiocarcinoma Patients: What is the Role of Chemoradiation?

Dr. Jane Rogers, MD Anderson Cancer Center (Dr. Rachna Shroff presented on behalf of Dr. Rogers)


Increasing Clinical Trials in CCA

Dr. Andrew Zhu, Massachusetts General Hospital, Session Chair
Dr. Mitesh Borad, Mayo Clinic
Dr. Eric Collisson, University of California San Francisco


Adoptive Cell Therapy – Patient Perspective

Melinda Bachini, CCF Patient Advocate




Overview of CCF Website

Donna Mayer, CCF Executive Director


Wrap-up and Next Steps

Alan Venook, UCSF

Nabeel Bardeesy, MGH

Stacie Lindsey, President, Cholangiocarcinoma Foundation